From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 253, P. 154959 - 154959

Published: Nov. 19, 2023

Language: Английский

---

N6-methyladenosine regulator YTHDF1 represses the CD8 + T cell-mediated antitumor immunity and ferroptosis in prostate cancer via m6A/PD-L1 manner

APOPTOSIS, Journal Year: 2023, Volume and Issue: 29(1-2), P. 142 - 153

Published: Sept. 12, 2023

Language: Английский

---

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(6)

Published: June 19, 2024

Abstract With the high incidence of urogenital tumors worldwide, urinary system are among top 10 most common in men, with prostate cancer ranking first and bladder fourth. Patients resistant often have poor prognosis. In recent years, researchers discovered numerous specific antigens, which has led to development several new anti-cancer drugs. Using protein analysis techniques, developed immune checkpoint inhibitors (ICIs) antibody-conjugated drugs (ADCs) for treatment advanced tumors. However, tumor resistance leads failure monotherapy. Therefore, clinical trials combination ICIs ADCs been carried out centers around world. This article reviewed phase 2 3 studies ICIs, ADCs, their highlight safe effective methods selecting individualized therapeutic strategies patients. activate system, whereas link monoclonal antibodies toxins, can achieve a synergistic effect when two combined. provides multiple advantages

Language: Английский

---

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(16), P. 12797 - 12797

Published: Aug. 14, 2023

Epidemiological data highlight prostate cancer as a significant global health issue, with high incidence and substantial impact on patients’ quality of life. The prevalence this disease is associated various factors, including age, heredity, race. Recent research in genetics has identified several genetic variants that may be an increased risk developing the disease. However, despite significance these findings, markers for are not currently utilized clinical practice reliable indicators In addition to genetics, epigenetic alterations also play crucial role development. Aberrant DNA methylation, changes chromatin structure, microRNA (miRNA) expression major events influence oncogenesis. Existing cancer, such prostate-specific antigen (PSA), have limitations terms sensitivity specificity. cost testing, follow-up procedures, treatment false-positive results overdiagnosis contributes overall healthcare expenditure. Improving effectiveness diagnosis prognosis requires either narrowing group by identifying new factors or enhancing specificity existing markers. Immunological biomarkers (both circulating intra-tumoral), immune response dysfunction, represent potentially useful area cancer. Our review emphasizes need novel immunological improve diagnosis, prognosis, management We most recent achievements identification provided monocytes tumor-associated macrophages (TAMs). monocyte-derived TAM-derived can enable establish missing links between predisposition, hormonal metabolism responses

Language: Английский

---

Drp1: Focus on Diseases Triggered by the Mitochondrial Pathway

Cell Biochemistry and Biophysics, Journal Year: 2024, Volume and Issue: 82(2), P. 435 - 455

Published: March 4, 2024

Language: Английский

---

CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells

Cancer Biology & Therapy, Journal Year: 2024, Volume and Issue: 25(1)

Published: March 17, 2024

Succinylation modification involves in the progression of human cancers. The present study aimed to investigate role CPT1A, which is a succinyltransferase prostate cancer (PCa). CCK-8 was used detect cell viability. Seahorse performed evaluate glycolysis. Luciferase assay transcriptional regulation. ChIP assess binding between factors with promoters. Co-IP proteins. We found that CPT1A highly expressed PCa tissues and lines. Silencing inhibited viability glycolysis cells. Mechanistically, promoted succinylation SP5, strengthened SP5 promoter PDPK1. activated PDPK1 transcription AKT/mTOR signal pathway. These findings might provide novel targets for diagnosis or therapy cancer.

Language: Английский

---

An In-Depth Look Into the Epidemiological and Etiological Aspects of Prostate Cancer: A Literature Review

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 4, 2023

Prostate cancer is the second most frequently diagnosed among men worldwide, and it represents a substantial worldwide health issue, primarily impacting as they grow older. Understanding its epidemiology etiology crucial for crafting efficient preventive measures enhancing treatment results. The of this disease provides valuable insights into prevalence distribution. Age critical factor, with risk prostate increasing advancing years. Incidence rates are notably higher in developed countries, suggesting role lifestyle environmental factors. Furthermore, there significant racial geographical disparities incidence, African-American experiencing both incidence more aggressive forms disease. On other hand, hormones, especially testosterone conversion to dihydrotestosterone (DHT), contribute cell growth and, potentially, cancer. Genetics also plays pivotal role, certain gene mutations, like Breast Cancer 1 & 2 (BRCA1 BRCA2), elevating risk. Dietary habits choices influence susceptibility, diets low fruits vegetables high saturated fats linked Chronic inflammation, often tied prostatitis, may further increase susceptibility This review article explores complex realm cancer, providing occurrence, factors that elevate risks, fundamental play emergence how we can prevent it.

Language: Английский

---

Artificial Intelligence in Urooncology: What We Have and What We Expect

Cancers, Journal Year: 2023, Volume and Issue: 15(17), P. 4282 - 4282

Published: Aug. 26, 2023

Artificial intelligence is transforming healthcare by driving innovation, automation, and optimization across various fields of medicine. The aim this study was to determine whether artificial (AI) techniques can be used in the diagnosis, treatment planning, monitoring urological cancers.We conducted a thorough search for original review articles published until 31 May 2022 PUBMED/Scopus database. Our included several terms related AI urooncology. Articles were selected with consensus all authors.Several types medical field. most common forms are machine learning (ML), deep (DL), neural networks (NNs), natural language processing (NLP) systems, computer vision. improve domains management urologic cancers, such as imaging, grading, nodal staging. also help identify appropriate diagnoses, options, even biomarkers. In majority these instances, accurate or sometimes superior doctors.AI have potential revolutionize treatment, cancers. use urooncology care expected increase future, leading improved patient outcomes better overall tumors.

Language: Английский

---

Advances in localized prostate cancer: a special focus on photothermal therapy

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: unknown, P. 176982 - 176982

Published: Sept. 1, 2024

Language: Английский

---

Correlation of the anticancer and pro-oxidant behavior and the structure of flavonoid-oxidovanadium(IV) complexes

Coordination Chemistry Reviews, Journal Year: 2023, Volume and Issue: 492, P. 215271 - 215271

Published: June 7, 2023

Language: Английский

---